Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-04-21
2010-10-19
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S006120, C435S375000, C435S377000
Reexamination Certificate
active
07816336
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of hydroxysteroid 11-beta dehydrogenase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hydroxysteroid 11-beta dehydrogenase 1. Methods of using these compounds for modulation of hydroxysteroid 11-beta dehydrogenase 1 expression and for treatment of diseases associated with expression of hydroxysteroid 11-beta dehydrogenase 1 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Barrachini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0198965 (2003-10-01), Freier
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: WO 01/30383 (2001-05-01), None
patent: WO 01/90093 (2001-11-01), None
Alberts, P. et al., “Selective Inhibition of 11βB-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains,”Endocrin. (2003) 144(11):4755-4762.
Berger, J. et al., “Peroxisome Proliferator-activated Receptor-g Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity,”J. Biol. Chem. (2001) 276(16):12629-12635.
Hatakeyama, H. et al., “11β-Hydroxysteroid Dehydrogenase Activities in Cultured Human Vascular Smooth Muscle Cells,”Front. Sci. Ser. (2000) 29:173-174.
Kotelevtsev, Y. et al., “11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress,”Proc. Natl. Acad. Sci. USA94:14924-14929, 1997.
Link, J. T., “Pharmacological regulation of hepatic glucose production,”Curr. Opin. Invest. Drugs(2003) 4(4):421-429.
MacKenzie, M. A. et al., “The Influence of Glycyrrhetinic Acid on Plasma Cortisol and Cortisone in Healthy Young Volunteers,”J. Clin. Endocrinol. Metab. (1990) 70(6):1637-1643.
Masuzaki, H. et al., “A Transgenic Model of Visceral Obesity and the Metabolic Syndrome,”Science(2001) 294:2166-2170.
Rask, E. et al., “Tissue-specific dysregulation of cortisol metabolism in human obesity,”J. Clin. Endocriol. Metab. (2001) 86(3):1418-1421.
Souness, G. W. et al., “11β-Hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism,”Steroids(2002) 67:195-201.
Stewart, P. M. et al., “Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolene and liquorice on 11β-hydroxysteroid dehydrogenase activity in man,”Clin. Sci.(1990) 78:49-54.3
Bjorntorp et al., “Obesity and Cortisol” Nutrition (2000) 16:924-936.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
New England Biolabs 1998/99 Catalog (cover page and pp. 121 and 284).
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Seckl et al., “Minireview: 1 1beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action” Endocrinology (2001) 142:1371-1376.
Shimojo et al., “Apparent mineralocorticoid excess syndromes” J. Endocrinol. Invest. (1995) 18:518-532.
Tannin et al., “The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization” J. Biol. Chem. (1991) 266:16653-16658.
International Search Report for application PCT/US03/12544 dated Apr. 12, 2003.
Isis Pharmaceuticals , Inc.
McDermott Will & Emery LLP
McGarry Sean R
LandOfFree
Antisense modulation of hydroxysteroid 11-beta dehydrogenase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of hydroxysteroid 11-beta dehydrogenase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of hydroxysteroid 11-beta dehydrogenase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195026